TECNOTREE
10.12.2020 13:55:11 CET | Business Wire | Press release
Further to the notification published on 30th June 2020, Tecnotree, the global provider of digital solutions for the telecom industry, has announced a strategic partnership with Kuwait Telecommunications Company - stc , a world-class digital leader providing innovative services and platforms to customers enabling the digital transformation in Kuwait, to deliver stc’s Enterprise Digitalization Program (EDP). The digital transformation project will provide stc ’s enterprise customers with a seamless and personalized omnichannel experience.
In its statement, stc mentioned that the three-year partnership supports the company’s vision to become a world-class digital leader in innovative telecom services and platforms across the region. The step forward will contribute to enhancing the customer experience through innovative solutions, facilitating business processes efficiently and expediting customer service responses across the various channels used by the company.
The EDP aims to transform stc ’s legacy BSS infrastructure with an open ecosystem composed of multi-speed digital architecture, enabling the company to rapidly deploy new capability models and integrate both partner and third-party digital channels into a single framework.
Tecnotree’s vast experience in driving digital transformation engagements globally will underpin the program. As stc ’s partner on this journey, Tecnotree brings unique capabilities to the project via its Digital BSS Suite 5 products, including Tecnotree Surge, an award-winning Digital Accelerator Platform that publishes TM Forum certified APIs. The two companies will use these tools together to help stc transition to a digital service provider of the future, enabling it to compete in the new digital telecom paradigm.
Engineer Fahad Abdulrahman Al Ali, Chief Technology Officer at stc, expressed his happiness in forming the strategic partnership, which serves as an additional step taken by the company to widen its offerings, its range of innovative digital solutions, and build the infrastructure of its 5G network.
He added, “Upgrading our digital services will provide our customers with enhanced connectivity solutions, thereby accelerating the deployment of smart applications and promoting digital transformation. This initiative builds on stc ’s commitment to continuously offer its enterprise customers with less restricted solutions that accelerate digital transformation with an aim to increase productivity and operational efficiency.”
Upon completion, the multi-phased transformation project will upgrade stc ’s current systems to state-of-the-art IT architecture and processes that will allow delivery of seamless and personalized omnichannel customer experiences via leveraging intelligent insights. This will enable stc to become a full digital ICT player and system integrator, whilst also expanding its services & solutions beyond mobility.
Commenting on the strategic partnership, Tecnotree CEO, Padma Ravichander, said, “We are delighted that stc has selected our award-winning Digital BSS Suite to support their digital transformation journey. As a world class digital leader, they have recognised that digitalization has become a core necessity to compete in today’s telecom industry. We look forward to using our TM Forum Gold-Badge certified products and years of global digital transformation experience to help stc emerge as the leader in the digitally connected ecosystem.”
View source version on businesswire.com: https://www.businesswire.com/news/home/20201210005533/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
International Human Rights Lawyer Jared Genser and Former White House Counsel Lanny J. Davis Join Legal and Advocacy Team Supporting Cambodian Businessman Yim Leak, Seiden Law LLP Announces18.9.2026 19:52:00 CEST | Press release
Jared Genser, one of the world's most recognized international human rights lawyers, and Lanny J. Davis, an adviser to former presidents George W. Bush and Bill Clinton, join the legal and advocacy team for Cambodian businessman Yim Leak and challenge what they call a coordinated smear campaign in Thailand. International human rights lawyer Jared Genser and Lanny J. Davis, who has close ties to two former US presidents and a worldwide reputation for defending those under attack with lies and smears, and for repairing the damage done to their reputations, have joined the legal and advocacy team supporting Cambodian businessman Yim Leak, Seiden Law LLP, which serves as Yim Leak's chief global counsel, announced today. Their first move is to hold the Thai government accountable, framing its conduct as either complicit in or willfully blind to a sustained smear campaign against Yim. Genser is Managing Director of Perseus Strategies, an international law firm. Over more than two decades, he
Ningbo FEED Meeting Confirms Full Confidence in Q1 2027 FID for Allied Biofuels’ US$6.1 Billion Presidential Decree-Backed SAF and e-SAF Project18.9.2026 17:38:00 CEST | Press release
Allied Biofuels has held a major Front-End Engineering Design (FEED) meeting at Sinopec’s office in Ningbo, China, bringing together Allied Biofuels, Sinopec Engineering Group Co., Ltd. of China, Topsoe A/S of Denmark, Sasol South Africa Limited, and Plug Power of the United States — the principal international engineering and technology providers supporting its US$6.1 billion Presidential Decree-backed Sustainable Aviation Fuel (SAF) and e-SAF project in Uzbekistan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918708077/en/ FEED Meeting - Ningbo, China At the joint FEED meeting of the project’s core engineering and technology stakeholders, the discussions established clear alignment on engineering responsibilities, technology interfaces, design deliverables, project integration and the coordinated execution programme required to advance the project through FEED. All stakeholders working on the project expressed full co
Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli® (Relacorilant)18.9.2026 14:00:00 CEST | Press release
Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth
Enhertu® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 14:00:00 CEST | Press release
Recommendation based on DESTINY-Breast05 phase 3 trial results that showed Enhertu reduced the risk of invasive disease recurrence or death by 53% versus T-DM1 Daiichi Sankyo and AstraZeneca’s Enhertu has the potential to become a new standard of care in this early breast cancer setting Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at th
CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 12:58:00 CEST | Press release
The information contained within this press release is for the purpose of scientific exchange.It is intended for scientific, financial and investor media only.If approved, Jyselecawill be indicated for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy.Despite the availability of multiple treatment options, nearly half of people living with axSpA do not respond adequately to current therapies, and just 10-20% reach inactive disease within 16-24 weeks of initiating treatment.CHMP’s positive opinion is based on findings from the OLINGUITO Phase 3 study, where improvements in the signs and symptoms of axSpA with filgotinib were observed early and maintained over 52 weeks of treatment.Jyselecais already approved in Europe and the United Kingdom, for the treatment of moderate to severe rheumatoid arthritis and ulcerative colitis. Alfasigma S.p.A, a global
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom